Shandong Bailong Chuangyuan Bio-Tech Co., Ltd.

SHSE:605016 Stock Report

Market Cap: CN¥5.8b

Shandong Bailong Chuangyuan Bio-Tech Future Growth

Future criteria checks 5/6

Shandong Bailong Chuangyuan Bio-Tech is forecast to grow earnings and revenue by 30.6% and 27.6% per annum respectively. EPS is expected to grow by 30.3% per annum. Return on equity is forecast to be 18.7% in 3 years.

Key information

30.6%

Earnings growth rate

30.3%

EPS growth rate

Food earnings growth22.3%
Revenue growth rate27.6%
Future return on equity18.7%
Analyst coverage

Low

Last updated31 Oct 2024

Recent future growth updates

Recent updates

Shandong Bailong Chuangyuan Bio-Tech's (SHSE:605016) Solid Profits Have Weak Fundamentals

Nov 06
Shandong Bailong Chuangyuan Bio-Tech's (SHSE:605016) Solid Profits Have Weak Fundamentals

Shandong Bailong Chuangyuan Bio-Tech Co., Ltd.'s (SHSE:605016) Intrinsic Value Is Potentially 78% Above Its Share Price

Oct 14
Shandong Bailong Chuangyuan Bio-Tech Co., Ltd.'s (SHSE:605016) Intrinsic Value Is Potentially 78% Above Its Share Price

Many Still Looking Away From Shandong Bailong Chuangyuan Bio-Tech Co., Ltd. (SHSE:605016)

Sep 29
Many Still Looking Away From Shandong Bailong Chuangyuan Bio-Tech Co., Ltd. (SHSE:605016)

Here's Why Shandong Bailong Chuangyuan Bio-Tech (SHSE:605016) Has Caught The Eye Of Investors

Aug 23
Here's Why Shandong Bailong Chuangyuan Bio-Tech (SHSE:605016) Has Caught The Eye Of Investors

Returns On Capital At Shandong Bailong Chuangyuan Bio-Tech (SHSE:605016) Have Hit The Brakes

Jun 26
Returns On Capital At Shandong Bailong Chuangyuan Bio-Tech (SHSE:605016) Have Hit The Brakes

Shandong Bailong Chuangyuan Bio-Tech Co., Ltd. (SHSE:605016) Analysts Are More Bearish Than They Used To Be

May 06
Shandong Bailong Chuangyuan Bio-Tech Co., Ltd. (SHSE:605016) Analysts Are More Bearish Than They Used To Be

Concerns Surrounding Shandong Bailong Chuangyuan Bio-Tech's (SHSE:605016) Performance

May 03
Concerns Surrounding Shandong Bailong Chuangyuan Bio-Tech's (SHSE:605016) Performance

If EPS Growth Is Important To You, Shandong Bailong Chuangyuan Bio-Tech (SHSE:605016) Presents An Opportunity

Mar 27
If EPS Growth Is Important To You, Shandong Bailong Chuangyuan Bio-Tech (SHSE:605016) Presents An Opportunity

Earnings and Revenue Growth Forecasts

SHSE:605016 - Analysts future estimates and past financials data (CNY Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20261,9524702904063
12/31/20251,5613652183193
12/31/20241,197271-169733
9/30/20241,035234-65217N/A
6/30/2024987221-44191N/A
3/31/2024926202-123201N/A
12/31/2023868193-117195N/A
9/30/2023825174-70187N/A
6/30/2023742163-29191N/A
3/31/2023719154-9167N/A
12/31/2022722151-26150N/A
9/30/2022732147-40141N/A
6/30/2022739131-13143N/A
3/31/2022717128-1095N/A
12/31/20216531044096N/A
9/30/202160599-1551N/A
6/30/202156697-3332N/A
3/31/20215409846119N/A
12/31/20205009637122N/A
9/30/20204799383150N/A
6/30/20204649275138N/A
3/31/202041677-158N/A
12/31/201942183864N/A
12/31/201835665189N/A
12/31/201731164N/A113N/A
12/31/201633665N/A60N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: 605016's forecast earnings growth (30.6% per year) is above the savings rate (2.8%).

Earnings vs Market: 605016's earnings (30.6% per year) are forecast to grow faster than the CN market (25.8% per year).

High Growth Earnings: 605016's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: 605016's revenue (27.6% per year) is forecast to grow faster than the CN market (13.8% per year).

High Growth Revenue: 605016's revenue (27.6% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: 605016's Return on Equity is forecast to be low in 3 years time (18.7%).

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/22 06:46
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Shandong Bailong Chuangyuan Bio-Tech Co., Ltd. is covered by 5 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Xia ShengCitic Securities Co., Ltd.
Lin YangGuosen Securities Co., Ltd.
Wei LiuHaitong International Research Limited